Hemostemix Inc (V:HEM) — Market Cap & Net Worth
Market Cap & Net Worth: Hemostemix Inc (HEM)
Hemostemix Inc (V:HEM) has a market capitalization of $8.18 Million (CA$11.31 Million) as of May 2, 2026. Listed on the V stock exchange, this Canada-based company holds position #27339 globally and #1183 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hemostemix Inc's stock price CA$0.06 by its total outstanding shares 188488541 (188.49 Million). Analyse cash efficiency ratio of Hemostemix Inc to see how efficiently the company converts income to cash.
Hemostemix Inc Market Cap History: 2015 to 2026
Hemostemix Inc's market capitalization history from 2015 to 2026. Data shows change from $1.50 Billion to $8.18 Million (-39.97% CAGR).
Hemostemix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hemostemix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HEM by Market Capitalization
Companies near Hemostemix Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Hemostemix Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Hemostemix Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Hemostemix Inc's market cap moved from $1.50 Billion to $ 8.18 Million, with a yearly change of -39.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$8.18 Million | -33.33% |
| 2025 | CA$12.27 Million | -25.00% |
| 2024 | CA$16.36 Million | +71.43% |
| 2023 | CA$9.54 Million | -61.11% |
| 2022 | CA$24.54 Million | +12.50% |
| 2021 | CA$21.82 Million | -77.14% |
| 2020 | CA$95.44 Million | +250.00% |
| 2019 | CA$27.27 Million | -87.50% |
| 2018 | CA$218.16 Million | +14.29% |
| 2017 | CA$190.89 Million | -65.00% |
| 2016 | CA$545.40 Million | -63.64% |
| 2015 | CA$1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Hemostemix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.18 Million USD |
| MoneyControl | $8.18 Million USD |
| MarketWatch | $8.18 Million USD |
| marketcap.company | $8.18 Million USD |
| Reuters | $8.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more